U.S. flag

An official website of the United States government

NM_000308.4(CTSA):c.146A>G (p.Gln49Arg) AND Combined deficiency of sialidase AND beta galactosidase

Germline classification:
Pathogenic/Likely pathogenic (3 submissions)
Last evaluated:
Jan 11, 2024
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000000408.9

Allele description [Variation Report for NM_000308.4(CTSA):c.146A>G (p.Gln49Arg)]

NM_000308.4(CTSA):c.146A>G (p.Gln49Arg)

Gene:
CTSA:cathepsin A [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
20q13.12
Genomic location:
Preferred name:
NM_000308.4(CTSA):c.146A>G (p.Gln49Arg)
HGVS:
  • NC_000020.11:g.45891714A>G
  • NG_008291.1:g.5763A>G
  • NG_033108.1:g.4574T>C
  • NM_000308.4:c.146A>GMANE SELECT
  • NM_001127695.3:c.146A>G
  • NM_001167594.3:c.146A>G
  • NP_000299.3:p.Gln49Arg
  • NP_001121167.1:p.Gln49Arg
  • NP_001161066.2:p.Gln49Arg
  • NC_000020.10:g.44520353A>G
  • NM_000308.4:c.146A>G
  • NR_133656.2:n.191A>G
Protein change:
Q49R; GLN49ARG
Links:
OMIM: 613111.0003; dbSNP: rs137854541
NCBI 1000 Genomes Browser:
rs137854541
Molecular consequence:
  • NM_000308.4:c.146A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001127695.3:c.146A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001167594.3:c.146A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NR_133656.2:n.191A>G - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Name:
Combined deficiency of sialidase AND beta galactosidase (GSL)
Synonyms:
CATHEPSIN A DEFICIENCY; Galactosialidosis; Goldberg syndrome; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0009737; MedGen: C0268233; Orphanet: 351; OMIM: 256540

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000020552OMIM
no assertion criteria provided
Pathogenic
(Jun 1, 1993)
germlineliterature only

PubMed (1)
[See all records that cite this PMID]

SCV004028593Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Pathogenic
(Jul 25, 2023)
germlineclinical testing

PubMed (3)
[See all records that cite these PMIDs]

Citation Link,

SCV004298091Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Likely pathogenic
(Jan 11, 2024)
germlineclinical testing

PubMed (4)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlinenot providednot providednot providednot providednot providednot providedliterature only
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

A case of galactosialidosis with a homozygous Q49R point mutation.

Matsumoto N, Gondo K, Kukita J, Higaki K, Paragison RC, Nanba E.

Brain Dev. 2008 Oct;30(9):595-8. doi: 10.1016/j.braindev.2008.01.012. Epub 2008 Apr 18.

PubMed [citation]
PMID:
18396002

Chemical chaperone treatment for galactosialidosis: Effect of NOEV on β-galactosidase activities in fibroblasts.

Hossain MA, Higaki K, Shinpo M, Nanba E, Suzuki Y, Ozono K, Sakai N.

Brain Dev. 2016 Feb;38(2):175-80. doi: 10.1016/j.braindev.2015.07.006. Epub 2015 Aug 7.

PubMed [citation]
PMID:
26259553
See all PubMed Citations (4)

Details of each submission

From OMIM, SCV000020552.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedliterature only PubMed (1)

Description

In a Japanese child with galactosialidosis (GSL; 256540), Shimmoto et al. (1993) identified an A-to-G transition in exon 2 of the CTSA gene, resulting in a gln49-to-arg (Q49R) substitution. This mutation, like the W65R (613111.0004), S90L (613111.0005), and Y249N (613111.0007) mutations, was found in compound heterozygosity with the common intron 7 splice site mutation (613111.0002).

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlinenot providednot providednot providednot providednot providednot providednot providednot provided

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV004028593.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (3)

Description

Variant summary: CTSA c.146A>G (p.Gln49Arg) results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 249136 control chromosomes (gnomAD). c.146A>G has been reported in the literature in individuals affected with Galactosialidosis (Shimmoto_1993, Hossain_2016, Matsumoto_2008). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function, finding that cells with the variant protein lacked carboxypeptidase, alpha-neuraminidase, and beta-galactosidase activity (Shimmoto_1993). The following publications have been ascertained in the context of this evaluation (PMID: 8514852, 26259553, 18396002). No submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Labcorp Genetics (formerly Invitae), Labcorp, SCV004298091.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (4)

Description

This sequence change replaces glutamine, which is neutral and polar, with arginine, which is basic and polar, at codon 67 of the CTSA protein (p.Gln67Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with galactosialidosis (PMID: 8514852, 18396002, 26259553). This variant is also known as Q49R. ClinVar contains an entry for this variant (Variation ID: 377). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CTSA protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects CTSA function (PMID: 8514852). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024